

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 317 957 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **04.11.92** (51) Int. Cl.⁵: **A61K 47/00, A61K 39/395, A61K 47/48**
- (21) Application number: **88119419.5**
- (22) Date of filing: **22.11.88**

(54) **Drug-monoclonal antibody conjugates.**

(30) Priority: **23.11.87 US 124313**

(43) Date of publication of application:
31.05.89 Bulletin 89/22

(45) Publication of the grant of the patent:
04.11.92 Bulletin 92/45

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:
WO-A-86/00527

(73) Proprietor: **Bristol-Myers Squibb Company**
345 Park Avenue
New York, N.Y. 10154(US)

(72) Inventor: **Senter, Peter D.**
211 Summit Avenue East, S421
Seattle Washington(US)

(74) Representative: **Kinzebach, Werner, Dr.**
Patentanwälte Reitstötter, Kinzebach und
Partner Sternwartstrasse 4 Postfach 86 06 49
W-8000 München 86(DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to anti-tumor drug-monoclonal antibody conjugates which are suitable for the delivery of cytotoxic agents to tumor cells.

Reference is made to EP-A-0 317 956 the same applicant.

The use of tumor-associated monoclonal antibodies as carriers for cytotoxic agents has received considerable attention in the past several years (Moller, 1982). The objective of much of this work has been to improve the efficacy of anticancer drugs while diminishing the undesired and oftentimes toxic side-effects. Investigations have been undertaken or proposed to accomplish this objective by use of antibody-drug conjugates in which the antibody serves to deliver the anticancer drug to the tumor.

In order for this approach to be effective, it is necessary that the antibody be highly tumor selective and that the drug be delivered in an active, cytotoxic form. Drugs such as methotrexate (Endo, 1987), daunomycin (Gallego et al., 1984), mitomycin C (MMC) (Ohkawa et al., 1986) and the vinca alkaloids (Rowland et al., 1986) have been attached to antibodies and the derived conjugates have been investigated for anti-tumor activities. In many cases, the sporadic activities of such conjugates can be attributed to the diminished activity of the drug when covalently attached to the antibody. Many examples exist in the art which illustrate linkage of antibodies to drugs by means of relatively stable chemical bonds which undergo slow non-specific release e.g. hydrolysis.

Additional problems may arise when the drug is released from the antibody, however, in a chemically modified form. Although the drug may now have access to its site of activity, the chemically modified drug can be significantly less potent.

Because of these considerations, there is a need for the development of new linking strategies, i.e. new drug-antibody conjugates, that can release chemically unmodified drug from the antibody in such a way that the drug can exert its maximal level of activity. Studies have shown that prodrug compounds that are benzyl carbamate disulfide derivatives of mitomycin C(MMC), mitomycin A (MMA), and daunomycin release chemically unmodified drug when the disulfide bond is reduced (Senter, cross-referenced patent application; see Fig. 1).

I have conceived that a prodrug strategy that relies on disulfide bond reduction for drug release may be ideally suited for the delivery of drugs to tumors with tumor associated antibodies since many solid tumors have been shown to exist in oxygen-deficient environments and possess enhanced levels of reducing agents such as glutathione, NADH and NADPH (Sartorelli, 1986). These reducing agents can effect the release of free drug from benzyl carbamate disulfide drug conjugates by reduction of the disulfide bond.

The use of benzyl carbamate disulfide linkers for drug-antibody conjugates may also be of use for the intracellular release of drugs in cases where the antibody is taken up inside the cell by receptor-mediated endocytosis. Intracellular thiols such as glutathione could then reduce the disulfide-linked conjugates.

This invention is a drug-antibody conjugate wherein the antibody and the drug are linked using disulfide benzyl carbamate, e.g. a MMC-antibody conjugate, or disulfide benzyl carbonate, e.g. an etoposide-antibody conjugate.

In another aspect, this invention refers to the use of the drug-monoclonal antibody conjugate according to this invention for preparing a pharmaceutical composition for treating tumors.

It has been demonstrated in the cross-referenced application that disulfide-bond reduction initiates a drug fragmentation process whereby the parent, i.e. unmodified, drug is released in an active, cytotoxic form. Furthermore, the rate of drug release can be controlled by sterically hindering the disulfide. Using the chemistry described in the cross-referenced application, there was no significant loss in drug activity. Substantially the same methodology has been found to be useful for the attachment of amine group-containing drugs, and equivalent hydroxyl group-containing drugs and protein toxins, to antibodies for site-directed immunotherapy.


Description of the Figures

Fig. 1 illustrates the pathway for elimination of MMC from its corresponding prodrug.

Fig. 2 illustrates the synthesis of a representative drug-monoclonal antibody conjugate according to this invention.

Fig. 3 illustrates HPLC comparative analytical results derivatives as prodrugs according to this invention.

This invention is an antitumor drug-monoclonal antibody conjugate having the general structural formula



wherein:

10 D is a antitumor drug moiety having pendant to the backbone thereof a chemically reactive functional group, by means of which the drug backbone is bonded to the disulfide benzyloxycarbonyl group, selected from a primary amino group represented by the formula R¹NH-, a secondary amino group represented by the formula R¹R²N-, and an alcohol group represented by the formula R¹O-;

15 R¹ is the backbone of said drug moiety when D is derived from a primary amino group, a secondary amino group, and an alcohol group wherein, in the case of a secondary amino group, when R¹ and R² are independent;


20 R², when R¹ and R² are independent, is selected from unsubstituted and substituted, and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenylalkyl wherein the phenyl moiety, when substituted, is substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

25 R¹ and R², when taken together in a functional group derived from a secondary amine, represent the backbone of the drug moiety, D, having a divalent group chemically bonded to the nitrogen atom constituting said secondary amino group;

30 R³ and R⁴, independently, are selected from H and unsubstituted and substituted, and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenylalkyl wherein the phenyl moiety, when substituted, is substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

m is an integer selected from 1 to 10; and

35 Ab represents a monoclonal antibody having a pendant amino group; and the substitution position of the group,



on the phenyl ring of the benzylcarbamate moiety is selected from the ortho- and para-positions.

45 Representative of said amino group-containing drugs are mitomycin-C, mitomycin-A, daunomycin, adriamycin, aminopterin, actinomycin, bleomycin, and derivatives thereof; and, representative of said alcohol group-containing drugs is etoposide.

The abbreviations used are as follows: MMC, mitomycin C; MMA, mitomycin A; DAU, daunomycin; PBS, phosphate buffered saline; HPLC, high pressure liquid chromatography; DDT, dithiothreitol; and Ab, monoclonal antibody.

50 The conjugate of the invention is useful for delivering said antitumor drug to the site of tumor cells in a mammal having enhanced levels of endogenous reducing agents including at least one member of the group of NADH, NADPH and glutathione. For this purpose the antitumor drug monoclonal antibody conjugate is contacted with endogenous reducing conditions such that the conjugate undergoes reductive cleavage to release free drug from the conjugate.

55 The conjugate according to this invention may be provided for use according to the method of this invention to treat a host, particularly a mammalian host such as, for example, an experimental animal host, affected by a tumor, as a pharmaceutical composition. The pharmaceutical composition comprises a antitumor effective amount, i.e. a tumor growth-inhibiting amount, of the conjugate according to this

invention and a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable excipients and adjuvants.

The antibody component of the immunoconjugate of the invention includes any antibody which binds specifically to a tumor-associated antigen. Examples of such antibodies include, but are not limited to, those which bind specifically to antigens found on carcinomas, melanomas, lymphomas and bone and soft tissue sarcomas as well as other tumors. Antibodies that remain bound to the cell surface for extended periods or that are internalized are preferred. These antibodies may be polyclonal or preferably, monoclonal and can be produced using techniques well established in the art [see, e.g., R. A. DeWeger et al., "Eradication Of Murine Lymphoma And Melanoma Cells By Chlorambucil-Antibody Complexes, *Immunological Rev.*, 62, pp. 29-45 (1982) (tumor-specific polyclonal antibodies produced and used in conjugates) and M. Yeh et al., "Cell Surface Antigens Of Human Melanoma Identified By Monoclonal Antibodies," *Proc. Natl. Acad. Sci.*, 76, p. 2927 (1979) and J. P. Brown et al. "Structural Characterization Of Human Melanoma-Associated Antigen p97 With Monoclonal Antibodies," *J. Immunol.*, 127 (no.2), pp. 539-546 (1981) (tumor-specific monoclonal antibodies produced)].

The pharmaceutical carrier ordinarily will be liquid to provide liquid compositions although liquid compositions would be expected to be more preferred because solid compositions would be expected to have lower absorption from the GI tract. The conjugates according to the invention may be provided as sterile soluble conjugates or compositions which can be dissolved or suspended in sterile water or other liquid medium to provide solutions and suspensions and emulsions for oral administration or for parenteral administration. Examples of liquid carriers suitable for oral administration include water, alcohol, polypropylene glycol, polyethylene glycol and mixtures of two or more of the above. Examples of liquid carriers suitable for parenteral use include water-for-injection, physiological saline, and other suitable sterile injection media. Suitable buffers for use with the liquid carrier to provide, generally, a suitable buffered isotonic solution include trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine, and L(+)-arginine.

The pharmaceutical composition will contain an amount of at least one conjugate of Formula I or mixture of one or more of said compounds of mixture thereof with another antitumor agent. The antitumor effective amount of compound of Formula I may be varied or adjusted widely depending upon the particular application, the form, the potency of the particular conjugate used, and the desired concentration of conjugate in the composition. Generally, the amount of active component will range between 0.5 and 90 % by weight based on total weight of composition.

In therapeutic use for treating a mammalian host, for example an experimental animal host, affected by a tumor, malignant or benign, the conjugates of this invention will be administered in an amount effective to inhibit the growth of the tumor, that is, a tumor growth-inhibiting amount will be in the range of 0.1 to 15 mg/kg of animal body weight/day. It is to be understood that the actual preferred dosage of conjugate will vary widely depending upon the requirements of the animal being treated, the composition being used, and the route of administration. Many factors that modify the action of the anti-neoplastic agent will be taken into account by one skilled in the art to which this invention pertains including, for example, age, body weight and sex of the animal host; diet; time of administration; rate of excretion; condition of the host; severity of the disease; and the like. Administration may be carried out simultaneously or periodically within the maximum tolerated dose. Optimal administration (or application) rates for a given set of conditions may be readily ascertained by those skilled in the art using conventional dosage determination tests.

The following examples are illustrative of the scope and utility of this invention and are not to be construed as limiting the scope of the invention. Unless otherwise indicated, all parts and percentages are by weight and temperatures are in degrees Celsius. The compounds and conjugates are numbered with reference to Figs. 1 & 2.

EXPERIMENTAL SECTION

Protein A purified monoclonal antibody designated L6 (IgG2a), which reacts to a glycolipid antigen on human lung carcinoma (Hellstrom et al., 1986) was provided by Drs. K.E. and I. Hellstrom (Oncogen, Seattle). The human tumor cell line, A549 was provided by Dr. J. Catino (Bristol-Myers Co., Wallingford).

Conjugate Binding Assay Immunoconjugates were serially diluted into growth media and 100 μ l aliquots were incubated at 4°C with 1×10^6 cells in 100 μ l growth media. After one hour, cells were washed twice and resuspended in 100 μ l medium containing 1:40 diluted goat anti-mouse IgG-FITC (Boehringer-Mannheim) for 20 minutes at 4°C. Cells were washed and analyzed using a Coulter Epics V fluorescence cell analyzer. For each experiment, similarly diluted MAb was used as a non-conjugated positive binding control.

In Vitro Cytotoxicity Assay. A549 cells in 0.4 ml of McCoys complete medium were plated at 1000 cells/well in 12-well tissue culture plates and then allowed to incubate overnight at 37°C. The cells were washed with RPMI media and conjugate in 0.4 ml of McCoys media were added. At periodic intervals (1, 3, 6 and 24 hr.), the cells were washed with RPMI to remove any unbound conjugate or drug, fresh McCoys media was added, and incubation was continued at 37°C for a total of 24 hr. The colonies were stained with crystal violet and were counted with a Optimax 40.10 Image Analyzer.

General Procedure - Preparation of 1 and 2. A solution of 137 mg (0.55 mmol) of para- or ortho-mercaptobenzyl alcohol, respectively, and 0.044 ml of pyridine (0.55 mmol) in 1 ml of dry dioxane was added over a 3 min period to a stirred solution of 0.032 ml (0.275 mmol) of trichloromethylchloroformate in 0.5 ml of dioxane. After stirring for 15 min., a solution of MMC (92 mg, 0.275 mmol) and triethylamine (0.153 ml, 1.1 mmol) in 4 ml of dioxane was rapidly added. After 5 min., the solvents were evaporated, and a solution of the residue in CH₂Cl₂ was extracted with satd. NaHCO₃, NaCl and dried (MgSO₄). The product was purified by flash chromatography on a 2x20cm SiO₂ column by first separating non-polar material with 30% ethyl acetate in petroleum ether (300ml), and then eluting the carbamate with 5% methanol in chloroform. The product, 1 and 2 respectively, was obtained as an amorphous blue solid which was dissolved in 3 ml of CH₂Cl₂ and added dropwise to 30 ml of pet ether. In the case of each of 1 and 2 respectively, a solid product was obtained having the following properties:

MMC Benzyl Carbamate Disulfide 1: yield 92% blue powder; mp 99° (dec); ¹H-NMR (pyr-d₅) δ 1.95 (s,3H,CH₃), 3.15 (s,3H,OCH₃), 3.4-4.2 (m,6H), 4.6-5.0 (m,2H), 5.20 (s,2H,ArCH₂), 5.6 (dd,1H), 6.9-7.8 (m,7H,ArH), 8.35-8.5 (m,1H,ArH); IR (KBr) ν 340, 2920, 1890, 1600, 1552 cm⁻¹; uv/vis (CH₃OH) λ max 356 nm (log ε = 4.31).

MMC Benzyl Carbamate Disulfide 2: yield 63% blue powder; mp 96-98°C; ¹H-NMR (pyr-d₅) δ 1.90 (s,3H,CH₃), 3.07 (s,3H,OCH₃), 3.4-3.55 (m,2H), 3.8-4.05 (m,3H), 4.6-5.0 (m,3H), 4.85 (s,3H), 5.35-5.70 (m,3H), 6.8-7.7 (m,7H,ArH), 8.35 (d,1H,ArH); IR (KBr) ν 3400, 1692, 1600, 1552 cm⁻¹; uv/vis (CH₃OH) λ max 365 nm (log ε = 4.32).

Preparation of Hydroxysuccinimide Ester 6. To a solution of 125 mg (0.205 mmol) of 1 in 5 ml of acetone was added 18 μl (0.205 mmol) of 3-mercaptopropionic acid. An additional 18 μl of 3-mercaptopropionic acid was added after 1h and the reaction was complete after a total of 1-1/2h. The solvent was removed under vacuum and the residue was purified by flash chromatography (SiO₂) using 10% methanol in methylene chloride as eluant. The acid (5) was used in the next step without further purification.

A solution of the acid (5, 0.186 mmole), N-hydroxysuccinimide (43 mg, 0.372 mmol) and dicyclohexyl carbodiimide (77 mg, 0.372 mmol) in 2 ml of dry DMF was stirred for 3 hrs. The precipitate was filtered and washed with ethyl acetate. After removal of the solvents under vacuum, the residue was purified by preparative TLC (SiO₂) using 10% isopropanol in methylene chloride as eluant. The hydroxysuccinimide ester (6) was obtained as a fine blue solid (26 mg). ¹H-NMR (360 MHz, CDCl₃) δ 1.75 (s,3H,CH₃), 2.85 (s,4H, succinimide CH₂), 2.8-3.1 (m,4H), 3.81 (s,3H,OCH₃), 3.20 (m,1H), 3.27-3.55 (m,3H), 3.70 (q,1H), 4.0 (br s, 1H), 4.33 (t,1H), 4.40 (d,1H), 4.6-5.4 (m,6H), 7.4 (g,4H,ArH).

Preparation of Hydroxysuccinimide Ester 8. The hydroxysuccinimide ester 8 was prepared from the pyridyl disulfide 1 and 2-mercapto-2-methyl propionic acid as described for the synthesis of 6. A fine blue solid (55 mg) was obtained starting with 100 mg of 1. ¹H-NMR (220 MHz, CDCl₃) δ 1.68 (s,6H, 2CH₃), 1.77 (s,3H,CH₃), 2.83 (s,4H, succinimide CH₂), 3.20 (s,3H,OCH₃), 3.25-3.75 (m,6H), 4.2-5.3 (m,6H), 7.40 (g,4H,ArH).

Preparation of Hydroxysuccinimide Ester 10. The hydroxysuccinimide ester 10 was prepared from the pyridyl disulfide 2 and 2-mercapto-2-methyl propionic acid as described for the synthesis of 6. The product, 10, was obtained as a blue solid (10 mg) starting with 71 mg of 2. ¹H-NMR (220 MHz, CDCl₃) δ 1.53 (s,3H,CH₃), 1.61 (s,3H,CH₃), 1.78 (s,3H,CH₃), 2.90 (s,4H, succinimide CH₂), 3.20 (s,3H,OCH₃), 3.4-3.8 (m,6H), 4.21 (t,1H), 4.40 (d,1H), 4.50 (br s, 2H), 4.90 (q,1H), 5.2-5.4 (m,4H), 7.2-7.4 (m,2H,ArH), 7.80 (d,2H,ArH).

Preparation of Drug-antibody Conjugates 11-13. Solutions of the hydroxysuccinimide esters, 6, 8, 10, (2.9-3.7mM) in acetonitrile were added to L6 antibody (2.61 mg/ml) in 1.5 ml of 50 mM borate buffer (pH 8.5) containing 100 mM NaCl at 30°C. The hydroxysuccinimide esters 8 and 10 (20-fold total molar excess) were added in four equal portions at 10 minute intervals while 6 (10-fold total molar excess) was added in two equal portions at 0 and 10 minutes. After 40 minutes, the precipitate was removed by centrifugation and the supernatants were dialyzed overnight against PBS at 4°C. The dialysates were gently rotated with about 0.5g SM-2 polystyrene beads (BioRad) for 10 min. at 4°C and then sterile filtered to remove any drug that was not covalently attached to the antibody. HPLC analyses (described below) of the conjugates

* para- or ortho- dithiopyridyl- or 3-nitrophenylbenzyl alcohol

indicated that no free drug or free-drug derivatives were present. The composition of the conjugates thus obtained were determined by the drug absorbance at 365 nm ($\epsilon = 21086$) and the antibody absorbance at 280 nm (Abs 280 nm, 1 mg/ml = 1.4) and were as follows: 11, 0.86 mg/ml Ab (1.29 mg total), drug/Ab = 4.38/1; 12 0.70 mg/ml Ab (1.05 mg total), drug/Ab = 5.14/1; 13, 1.07 mg/ml Ab (1.65 mg total), drug/Ab = 5.25/1.

An anti-tumor drug-antibody conjugate wherein the drug component is the alcohol group containing drug etoposide, whereby the etoposide is bonded to the disulfide benzyl moiety by a carbonate linkage rather than a carbamate linkage, is prepared by following substantially the foregoing procedures by first providing an etoposide benzyl carbonate disulfide by substituting etoposide (162 mg, 0.275 mmol) for MMC and then using the resulting etoposide benzyl carbonate disulfide in the place of the MMC benzyl carbamate disulfide in the remaining steps of the conjugate preparation.

Of course, MMA, daunomycin, adriamycin and the other amino group containing drugs can be used in place of MMC in the foregoing examples.

Stability of Conjugates. The conjugates 11-13 were diluted with an equal volume of growth media containing RPMI and 10% fetal calf serum. The solutions were incubated at 37°C. Portions (0.25 ml) were applied to protein-A columns (0.25 ml) at periodic intervals and the columns were washed with PBS to remove any unbound material. The bound conjugates were eluted with 100 mM acetic acid containing 150 mM NaCl (0.5 ml) and quickly neutralized. Spectrophotometric analysis was used to determine the composition of the conjugates.

REACTION OF CONJUGATES WITH DITHIOTHREITOL

To a solution of the drug-antibody conjugates, 11-13 in PBS, was added dithiothreitol (final conc. 0.2 mM). After 19 hrs at room temperature, aliquots were analyzed by HPLC, using a 10 cm Whatman Partasil 5 ODS-3 reverse phase (C-18) column and the following gradient system: 30% CH₃OH in 0.1% acetate (pH 6) to 95% CH₃OH in 6 min; continued for 8 min; flow rate 2 ml/min; monitored at 340 nm.

RESULTS AND DISCUSSION

Preparation of Conjugates. The hydroxysuccinimide esters 6, 8 and 10 were prepared from mitomycin C benzylcarbamate pyridyl disulfides 1 and 2 in a two-step process involving disulfide exchange with a thiol-substituted acid followed by esterification of the acid with N-hydroxysuccinimide (Fig. 2). Reaction of the hydroxysuccinimide esters with the antibody L6 at pH 8.5 resulted in the formation of antibody-MMC conjugates 11-13. The conjugates were free of any non-covalently attached MMC and were characterized by HPLC and uv/vis spectroscopy. It was possible to attach as many as six MMC molecules to L6 using the chemistry described. Presumably, amino groups on the antibody displace the hydroxysuccinimide esters on the activated drugs and amide bonds are formed between the antibody and the drug derivatives.

Release of Mitomycin C from the Conjugates. The ability of benzyl carbamate disulfide drug derivatives to undergo drug elimination upon disulfide bond reduction has been studied in some detail (Senter *supra*). The presumed mechanism for the fragmentation reaction of disulfide bond in the conjugates, 11-13, would lead to the release of MMC.

The L6-MMC conjugate, 11 was reduced with excess dithiothreitol, and the reaction was monitored by HPLC. It was observed that MMC release occurred, as evidenced by comparison to an authentic sample (Fig. 3). In the absence of a reducing agent, the conjugates in PBS were completely stable under the reaction conditions.

It was of interest to determine whether steric hindrance of the disulfide bond would have an effect on the stability of the drug antibody conjugates. It has previously been reported that ricin-A chain immunotoxins with hindered disulfides were more stable *in vitro* than similar non-hindered immunotoxins (Worrell, et al., 1986).

The conjugates were incubated at 37°C in 1:1 solutions of PBS and growth media containing RPMI and 10% fetal calf serum. The amount of drug that remained antibody bound was determined after the conjugates were re-isolated on a protein-A affinity column. After 24h, it was found that 11, 12 and 13 released 40%, 21% and 9% of the bound drug respectively. Therefore, increased conjugate stability can be achieved by increasing the degree to which the disulfide bond is hindered.

Binding and In Vitro Cytotoxicities of the Conjugates. The conjugates were tested for their ability to bind to receptors on the A549 lung carcinoma cell line. Fluorescence activated cell sorting indicated that all three conjugates bound to the cells just as well as the unmodified antibody. The chemistry used for drug attachment did not apparently affect the avidity of the antibody.

The cytotoxic activities of the conjugates on the A549 cell line was determined over a range of exposure times (Table 1). The least hindered conjugate, 11, displayed significant growth inhibition after only a 3h exposure, while the more hindered conjugates, 12 and 13, took considerably longer before a cytotoxic effect was observed. After 24 hours all three conjugates were highly cytotoxic. The IC-50 values obtained for conjugates 11, 12 and 13 after a 24 hour exposure were 55nM, 64nM, and 59nM respectively. The IC-50 value for free MMC after a 24 hour exposure was 50nM. Therefore, the conjugation chemistry preserves the activity of the drug.

REFERENCES

- 10 Endo, N., Kato, Y., Takeda, Y., Saito, M., Umemoto, N., Kishida, K., and Hara, T. In vitro cytotoxicity of a human serum-albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Research 47, 1076-1080 (1987).
- Gallego, J., Price, M.R., and Baldwin, R.W. Preparation of four daunomycin-monoclonal antibody 791T/36
15 conjugates with antitumor activity. Int. J. Cancer, 33, 737-744 (1984).
- Hellstrom, I., Beaumier, P.L. and Hellstrom, K.E. Antitumor effects of Lb, and IgG2A antibody that reacts with most human carcinomas Proc. Natl. Acad. Sci. 83, 7059-7063 (1986).
- Moller, G. (Ed): Antibody carriers of drugs and toxins in tumor therapy. Immunol. Rev., 62 (1982).
- Ohkawa, K., Tsukada, Y., Hibi, N., Umemoto, N., and Hara, T. Selective in vitro and in vivo growth inhibition
20 against human yolk sac tumor cell lines by purified antibody against human α -fetoprotein conjugated with mitomycin C via human serum albumin. Cancer Immunol. Immunother. 23, 81-86 (1986).
- Rowland, G.F., Simmonds, R.G., Gore, V.A., Marsden, C.H. and Smith, W. Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumor xenograft. Cancer Immunol. Immunother. 21, 183-187 (1986).
- 25 Sartorelli, A.C. The role of mitomycin antibiotics in the chemotherapy of solid tumors. Biochem. Pharm. 35, 67-69 (1986).
- Worrell, N.R., Cumber, A.J., Parnell, G.D., Mirza, A., Forrester, J.A. and Ross, W.C.J. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anti-cancer Drug Design 1, 179-188, (1986).

30

35

40

45

50

55

TABLE 1

Percent inhibition of A549 colony formation after exposure to conjugates 11-13 at 10µg/ml L6. The effect of exposure time.

15

Conjugate		% inhibition of colony formation			
20	(10µg/ml antibody	1h	3h	6h	24h
25					
	11	15%	45%	70%	95%
30	12	12%	25%	0%	95%
	13	10%	10%	0%	95%


35

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. An anti-tumor drug-monoclonal antibody conjugate having the general structural formula:

45



50

wherein:

D is a anti-tumor drug moiety having pendant to the backbone thereof a chemically reactive functional group, by means of which the drug backbone is bonded to the disulfide benzyloxycarbonyl group, selected from a primary amino group represented by the formula R^1NH- , a secondary amino group represented by the formula R^1R^2N- , and an alcohol group represented by the formula R^1O- ;

55

R^1 is the backbone of said drug moiety when D is derived from a primary amino group, a secondary amino group, and an alcohol group wherein, in the case of a secondary amino group, when R^1 and R^2 are independent.

R^2 , when R^1 and R^2 are independent, is selected from unsubstituted and substituted and branched


and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenalkyl wherein the phenyl moiety, when substituted, as substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

R¹ and R², when taken together in a functional group derived from a secondary amine, represent the backbone of the drug moiety, D, having a divalent group chemically bonded to the nitrogen atom constituting said secondary amino group; and

R³ and R⁴, independently, are selected from H and unsubstituted and substituted, and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenylalkyl wherein the phenyl moiety, when substituted, is substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

m is an integer selected from 1 to 10; and

Ab represents a monoclonal antibody having a pendant amino group; and the orientation of the group,




on the phenyl ring of the benzylcarbamate moiety is selected from the ortho- and para-positions.


2. A compound according to claim 1 wherein the drug moiety, D, is a member selected from primary amine-containing and secondary amine-containing drugs.
3. A compound according to claim 2 wherein the drug moiety, D, is a member selected from mitomycin-C, mitomycin-A, daunomycin, adriamycin, aminopterin, actinomycin, bleomycin, and derivatives thereof.
4. A compound according to claim 1 wherein the drug moiety, D, is an alcohol group-containing drug.
5. A compound according to claim 4 wherein the drug moiety, D, is etoposide.
6. A process for preparing the conjugates of claims 1 to 5 which comprises reacting para- or ortho-mercaptobenzyl alcohol with PySCl, wherein Py is pyridyl, preferably 2-pyridyl, or 3-nitrophenyl, reacting the so obtained compound with trichloromethylchloroformate in an inert organic solvent in the presence of a base, preferably pyridine, reacting the so obtained compound with an antitumor drug D, wherein D is as defined in claim 1 in an inert organic solvent and preferably in the presence of a base, to obtain a compound of the general formula




reacting the so obtained compound with a mercaptocarboxylic acid of the general formula:



wherein R³, R⁴ and m are as defined in claim 1, in an inert organic solvent to obtain a compound of the general formula:



wherein R is hydrogen,
 reacting the so obtained carboxylic acid with N-hydroxysuccinimide and a condensation agent,
 preferably dicyclohexyl carbodiimide, in an inert organic solvent to obtain the hydroxysuccinimide ester
 of the above general formula, wherein R is




and reacting the so obtained compound with an antibody Ab-NH₂, wherein Ab is as defined in claim 1,
 in an inert reaction medium.

7. A pharmaceutical composition comprising at least one antibody conjugate of any one of claims 1 to 5
 and a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable
 excipients and adjuvants.
8. A process for preparing the composition of claim 7 which comprises incorporating at least one
 compound of claims 1 to 5 into a pharmaceutically acceptable carrier and optionally, conventional
 pharmaceutically acceptable excipients and adjuvants.
9. The use of at least one antibody conjugate according to any one of claims 1 to 5 for preparing a
 pharmaceutical composition for treating tumors.

Claims for the following Contracting State : ES

1. A process for preparing an anti-tumor drug-monoclonal antibody conjugate having the general structural
 formula:



wherein:

D is a anti-tumor drug moiety having pendant to the backbone thereof a chemically reactive
 functional group, by means of which the drug backbone is bonded to the disulfide benzyloxycarbonyl
 group, selected from a primary amino group represented by the formula R¹NH-, a secondary amino
 group represented by the formula R¹R²N-, and a alcohol group represented by the formula R¹O-;

R¹ is the backbone of said drug moiety when D is derived from a primary amino group, a
 secondary amino group, and an alcohol group wherein, in the case of a secondary amino group, when
 R¹ and R² are independent.

R², when R¹ and R² are independent, is selected from unsubstituted and substituted and branched
 and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to
 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted


phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenalkyl wherein the phenyl moiety, when substituted, as substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

R^1 and R^2 , when taken together in a functional group derived from a secondary amine, represent the backbone of the drug moiety, D, having a divalent group chemically bonded to the nitrogen atom constituting said secondary amino group; and

R^3 and R^4 , independently, are selected from H and unsubstituted and substituted, and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenylalkyl wherein the phenyl moiety, when substituted, is substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

m is an integer selected from 1 to 10; and

Ab represents a monoclonal antibody having a pendant amino group; and the orientation of the group,




on the phenyl ring of the benzylcarbamate moiety is selected from the ortho- and para-positions,


which comprises reacting para- or ortho- mercaptobenzyl alcohol with PySCI, wherein Py is pyridyl, preferably 2-pyridyl, or 3-nitrophenyl,

reacting the so obtained compound with trichloromethylchloroformate in an inert organic solvent in the presence of a base, preferably pyridine,


reacting the so obtained compound with an antitumor drug D, wherein D is as defined above in an inert organic solvent and preferably in the presence of a base, to obtain a compound of the general formula



reacting the so obtained compound with a mercaptocarboxylic acid of the general formula:



wherein R^3 , R^4 and m are as defined above, in an inert organic solvent to obtain a compound of the general formula:



wherein R is hydrogen,

reacting the so obtained carboxylic acid with N-hydroxysuccinimide and a condensation agent, preferably dicyclohexyl carbodiimide, in an inert organic solvent to obtain the hydroxysuccinimide ester of the above general formula, wherein R is



5

10 and reacting the so obtained compound with an antibody Ab-NH₂, wherein Ab is as defined above, in an inert reaction medium.

2. A process according to claim 1 wherein the drug moiety, D, is a member selected from primary amine-containing and secondary amine-containing drugs.

15

3. A process according to claim 2 wherein the drug moiety, D, is a member selected from mitomycin-C, mitomycin-A, daunomycin, adriamycin, aminopterin, actinomycin, bleomycin, and derivatives thereof.

4. A process according to claim 1 wherein the drug moiety, D, is an alcohol group-containing drug.

20

5. A process according to claim 4 wherein the drug moiety, D, is etoposide.

6. A process for preparing a pharmaceutical composition comprising at least one antibody conjugate as defined in any one of claims 1 to 5 and a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable excipients and adjuvants, which comprises incorporating at least one compound of claims 1 to 5 into a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable excipients and adjuvants.

25


7. The use of at least one antibody conjugate according to any one of claims 1 to 5 for preparing a pharmaceutical composition for treating tumors.

30

Claims for the following Contracting State : GR

1. An anti-tumor drug-monoclonal antibody conjugate having the general structural formula:

35



40

wherein:

45

D is a anti-tumor drug moiety having pendant to the backbone thereof a chemically reactive functional group, by means of which the drug backbone is bonded to the disulfide benzyloxycarbonyl group, selected from a primary amino group represented by the formula R¹NH-, a secondary amino group represented by the formula R¹R²N-, and a alcohol group represented by the formula R¹O-;

50

R¹ is the backbone of said drug moiety when D is derived from a primary amino group, a secondary amino group, and an alcohol group wherein, in the case of a secondary amino group, when R¹ and R² are independent.

55


R², when R¹ and R² are independent, is selected from unsubstituted and substituted and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenalkyl wherein the phenyl moiety, when substituted, as substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

R¹ and R², when taken together in a functional group derived from a secondary amine, represent the backbone of the drug moiety, D, having a divalent group chemically bonded to the nitrogen atom constituting said secondary amino group; and

R³ and R⁴, independently, are selected from H and unsubstituted and substituted, and branched and straight-chain alkyl groups having 1-10 carbon atoms wherein the substituent is selected from 1 to 3 alkoxy groups having 1 to 3 carbon atoms and 1 to 3 halo groups; unsubstituted and substituted phenyl wherein the substituent is selected from 1 to 3 alkyl groups having 1 to 3 carbon atoms, 1 to 3 alkoxy groups having 1 to 3 carbon atoms, and 1 to 3 halo groups; and unsubstituted and substituted phenylalkyl wherein the phenyl moiety, when substituted, is substituted as defined above in the case of substituted phenyl and the alkyl moiety is a polyalkylene group having 1 to 3 carbon atoms;

m is an integer selected from 1 to 10; and

Ab represents a monoclonal antibody having a pendant amino group; and the orientation of the group,



on the phenyl ring of the benzylcarbamate moiety is selected from the ortho- and para-positions.


2. A compound according to claim 1 wherein the drug moiety, D, is a member selected from primary amine-containing and secondary amine-containing drugs.

3. A compound according to claim 2 wherein the drug moiety, D, is a member selected from mitomycin-C, mitomycin-A, daunomycin, adriamycin, aminopterin, actinomycin, bleomycin, and derivatives thereof.

4. A compound according to claim 1 wherein the drug moiety, D, is an alcohol group-containing drug.

5. A compound according to claim 4 wherein the drug moiety, D, is etoposide.


6. A process for preparing the conjugates of claims 1 to 5 which comprises reacting para- or ortho-mercaptobenzyl alcohol with PySCl, wherein Py is pyridyl, preferably 2-pyridyl, or 3-nitrophenyl, reacting the so obtained compound with trichloromethylchloroformate in an inert organic solvent in the presence of a base, preferably pyridine, reacting the so obtained compound with an antitumor drug D, wherein D is as defined in claim 1 in an inert organic solvent and preferably in the presence of a base, to obtain a compound of the general formula



reacting the so obtained compound with a mercaptocarboxylic acid of the general formula:



wherein R³, R⁴ and m are as defined in claim 1, in an inert organic solvent to obtain a compound of the general formula:



wherein R is hydrogen,
 reacting the so obtained carboxylic acid with N-hydroxysuccinimide and a condensation agent,
 preferably dicyclohexyl carbodiimide, in an inert organic solvent to obtain the hydroxysuccinimide ester
 of the above general formula, wherein R is




and reacting the so obtained compound with an antibody Ab-NH₂, wherein Ab is as defined in claim 1,
 in an inert reaction medium.

7. A process for preparing a pharmaceutical composition comprising at least one antibody conjugate of any one of claims 1 to 5 and a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable excipients and adjuvants, which comprises incorporating at least one compound of claims 1 to 5 into a pharmaceutically acceptable carrier and optionally, conventional pharmaceutically acceptable excipients and adjuvants.
8. The use of at least one antibody conjugate according to any one of claims 1 to 5 for preparing a pharmaceutical composition for treating tumors.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Konjugat aus einem Antitumor-Arzneistoff und einem monoklonalen Antikörper, wobei das Konjugat die allgemeine Strukturformel:



aufweist, worin:


- D einen Antitumor-Arzneistoffrest bedeutet, der an seinem Gerüst eine chemisch-reaktive funktionelle Gruppe aufweist, durch welche das Arzneistoffgerüst an die Disulfidbenzyloxycarbonylgruppe gebunden ist, ausgewählt unter einer primären Aminogruppe der Formel R¹NH-, einer sekundären Aminogruppe der Formel R¹R²N-, und einer Alkoholgruppe der Formel R¹O-
- wobei
- R¹ das Gerüst des Arzneistoffrestes ist, wenn D von einer primären Aminogruppe, einer sekundären Aminogruppe und einer Alkoholgruppe abgeleitet ist, wobei im Falle einer sekundären Aminogruppe, R¹ und R² unabhängig sind,
- R² wenn R¹ und R² unabhängig sind, ausgewählt ist unter unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;

R¹ und R², wenn sie zusammengekommen in einer von einem sekundären Amin abgeleiteten funktionellen Gruppe sind, das Gerüst des Arzneistoffrestes D bedeuten, das eine divalente Gruppe aufweist, die chemisch an das Stickstoffatom, welches die sekundäre Aminogruppe bildet, gebunden ist; und

R³ und R⁴ unabhängig voneinander ausgewählt sind unter H und unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;

m eine ganze Zahl bedeutet, die ausgewählt ist von 1 bis 10; und

Ab einen monoklonalen Antikörper mit einer daran hängenden Aminogruppe bedeutet; und wobei die Orientierung der Gruppe



am Phenylring der Benzylcarbamateinheit ausgewählt ist unter der ortho- und para-Position.

2. Verbindung nach Anspruch 1, wobei der Arzneistoffrest D ausgewählt ist unter Arzneistoffen mit einer primären Amingruppe und einer sekundären Amingruppe.

3. Verbindungen nach Anspruch 2, wobei der Arzneistoffrest D ausgewählt ist unter Mitomycin-C, Mitomycin-A, Daunomycin, Adriamycin, Aminopterin, Actinomycin, Bleomycin und Derivaten davon.


4. Verbindung nach Anspruch 1, wobei der Arzneistoffrest D ein Arzneistoff mit einer Alkoholgruppe ist.

5. Verbindung nach Anspruch 4, wobei der Arzneistoffrest D Etoposid ist.

6. Verfahren zur Herstellung der Konjugate der Ansprüche 1 bis 5, wobei man para- oder ortho-Mercaptobenzylalkohol mit PySCI, worin Py für Pyridyl, vorzugsweise 2-Pyridyl, oder 3-Nitrophenyl steht, zur Reaktion bringt,

die so erhaltene Verbindung mit Trichlormethylchlorformiat in einem inerten organischen Lösungsmittel in Gegenwart einer Base, vorzugsweise Pyridin, umsetzt,

die so erhaltene Verbindung mit einem Antitumorzneistoff D, worin D die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten organischen Lösungsmittel und vorzugsweise in Gegenwart einer Base zu einer Verbindung der allgemeinen Formel




umsetzt,

die so erhaltene Verbindung mit einer Mercaptocarbonsäure der allgemeinen Formel:



worin R³, R⁴ und m die in Anspruch 1 angegebenen Bedeutungen besitzen in einem inerten organischen Lösungsmittel zu einer Verbindung der allgemeinen Formel:



5

10 worin R ein Wasserstoffatom bedeutet, umgesetzt, die so erhaltene Carbonsäure mit N-Hydroxysuccinimid und einem Kondensationsmittel, vorzugsweise Dicyclohexylcarbodiimid, in einem inerten organischen Lösungsmittel zum Hydroxysuccinimidester der oben angegebenen allgemeinen Formel, worin R für

15



20

steht, umgesetzt und die so erhaltene Verbindung mit einem Antikörper Ab-NH₂, worin Ab die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten Reaktionsmedium zur Reaktion bringt.


- 25 7. Pharmazeutisches Mittel, enthaltend wenigstens ein Antikörperkonjugat nach einem der Ansprüche 1 bis 5 und einen pharmazeutisch verträglichen Träger und gegebenenfalls übliche pharmazeutisch verträgliche Excipienten und Adjuvantien.
8. Verfahren zur Herstellung des Mittels nach Anspruch 7, wobei man wenigstens eine Verbindung der Ansprüche 1 bis 5 einem pharmazeutisch verträglichen Träger und gegebenenfalls üblichen pharmazeutisch verträglichen Excipienten und Adjuvantien einverleiht.
- 30 9. Verwendung wenigstens eines Antikörperkonjugates nach einem der Ansprüche 1 bis 5 zur Herstellung eines pharmazeutischen Mittels zur Tumorbehandlung.

35

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung eines Konjugates aus einem Antitumor-Arzneistoff und einem monoklonalen Antikörper, wobei das Konjugat die allgemeine Strukturformel:

40



45

aufweist, worin:

- 50 D einen Antitumor-Arzneistoffrest bedeutet, der an seinem Gerüst eine chemisch-reaktive funktionelle Gruppe aufweist, durch welche das Arzneistoffgerüst an die Disulfidbenzyloxycarbonylgruppe gebunden ist, ausgewählt unter einer primären Aminogruppe der Formel R¹NH-, einer sekundären Aminogruppe der Formel R¹R²N-, und einer Alkoholgruppe der Formel R¹O-

55


- wobei R¹ das Gerüst des Arzneistoffrestes ist, wenn D von einer primären Aminogruppe, einer sekundären Aminogruppe und einer Alkoholgruppe abgeleitet ist, wobei im Falle einer sekundären Aminogruppe, R¹ und R² unabhängig sind,

R^2 wenn R^1 und R^2 unabhängig sind, ausgewählt ist unter unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;


R^1 und R^2 , wenn sie zusammengekommen in einer von einem sekundären Amin abgeleiteten funktionellen Gruppe sind, das Gerüst des Arzneistoffrestes D bedeuten, das eine divalente Gruppe aufweist, die chemisch an das Stickstoffatom, welches die sekundäre Aminogruppe bildet, gebunden ist; und R^3 und R^4 unabhängig voneinander ausgewählt sind unter H und unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;

m eine ganze Zahl bedeutet, die ausgewählt ist von 1 bis 10; und

Ab einen monoklonalen Antikörper mit einer daran hängenden Aminogruppe bedeutet; und wobei die Orientierung der Gruppe




am Phenylring der Benzylcarbamateinheit ausgewählt ist unter der ortho- und para-Position, wobei man para- oder ortho-Mercaptobenzylalkohol mit PySCl, worin Py für Pyridyl, vorzugsweise 2-Pyridyl, oder 3-Nitrophenyl steht, zur Reaktion bringt, die so erhaltene Verbindung mit Trichlormethylchlorform in einem inerten organischen Lösungsmittel in Gegenwart einer Base, vorzugsweise Pyridin, umsetzt, die so erhaltene Verbindung mit einem Antitumorzneistoff D, worin D die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten organischen Lösungsmittel und vorzugsweise in Gegenwart einer Base zu einer Verbindung der allgemeinen Formel



umsetzt, die so erhaltene Verbindung mit einer Mercaptocarbonsäure der allgemeinen Formel:




worin R^3 , R^4 und m die in Anspruch 1 angegebenen Bedeutungen besitzen in einem inerten organischen Lösungsmittel zu einer Verbindung der allgemeinen Formel:



worin R ein Wasserstoffatom bedeutet, umgesetzt,
die so erhaltene Carbonsäure mit N-Hydroxysuccinimid und einem Kondensationsmittel, vorzugsweise Dicyclohexylcarbodiimid, in einem inerten organischen Lösungsmittel zum Hydroxysuccinimidester der oben angegebenen allgemeinen Formel, worin R für

5



10


15 steht, umgesetzt und
die so erhaltene Verbindung mit einem Antikörper Ab-NH₂, worin Ab die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten Reaktionsmedium zur Reaktion bringt.

2. Verfahren nach Anspruch 1, wobei der Arzneistoffrest D ausgewählt ist unter Arzneistoffen mit einer primären Aminogruppe und einer sekundären Aminogruppe.
3. Verfahren nach Anspruch 2, worin der Arzneistoffrest D ausgewählt ist unter Mitomycin-C, Mitomycin-A, Daunomycin, Adriamycin, Aminopterin, Actinomycin, Bleomycin und Derivatgen davon.
4. Verfahren nach Anspruch 1, wobei der Arzneistoffrest D ein Arzneistoff mit einer Alkoholgruppe ist.
5. Verfahren nach Anspruch 4, wobei der Arzneistoffrest D Etoposid ist.
6. Verfahren zur Herstellung eines Arzneimittels, welches wenigstens ein Antikörperkonjugat nach einem der Ansprüche 1 bis 5 und einem pharmazeutisch verträglichen Träger und gegebenenfalls übliche pharmazeutisch verträgliche Exzipienten und Adjuvantien enthält, wobei man wenigstens eine Verbindung der Ansprüche 1 bis 5 einem pharmazeutisch verträglichen Träger und gegebenenfalls üblichen pharmazeutisch verträglichen Exzipienten und Adjuvantien einverleibt.
7. Verwendung wenigstens eines Antikörperkonjugates nach einem der Ansprüche 1 bis 5 zur Herstellung eines pharmazeutischen Mittels zur Tumorbehandlung.

Patentansprüche für folgenden Vertragsstaat : GR

1. Konjugat aus einem Antitumor-Arzneistoff und einem monoklonalen Antikörper, wobei das Konjugat die allgemeine Strukturformel:

45



50

aufweist, worin:

- D einen Antitumor-Arzneistoffrest bedeutet, der an seinem Gerüst eine chemisch-reaktive funktionelle Gruppe aufweist, durch welche das Arzneistoffgerüst an die Disulfidbenzyloxycarbonylgruppe gebunden ist, ausgewählt unter einer primären Aminogruppe der Formel R¹NH-, einer sekundären Aminogruppe der Formel R¹R²N-, und einer Alkoholgruppe der Formel R¹O-

55

wobei

- R¹ das Gerüst des Arzneistoffrestes ist, wenn D von einer primären Aminogruppe, einer sekun-

dären Aminogruppe und einer Alkoholgruppe abgeleitet ist, wobei im Falle einer sekundären Aminogruppe, R¹ und R² unabhängig sind,


R² wenn R¹ und R² unabhängig sind, ausgewählt ist unter unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;

R¹ und R², wenn sie zusammengekommen in einer von einem sekundären Amin abgeleiteten funktionellen Gruppe sind, das Gerüst des Arzneistoffrestes D bedeuten, das eine divalente Gruppe aufweist, die chemisch an das Stickstoffatom, welches die sekundäre Aminogruppe bildet, gebunden ist; und

R³ und R⁴ unabhängig voneinander ausgewählt sind unter H und unsubstituierten und substituierten, verzweigten und geradkettigen Alkylgruppen mit 1 bis 10 Kohlenstoffatomen, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; unsubstituiertem und substituiertem Phenyl, wobei der Substituent ausgewählt ist unter 1 bis 3 Alkylgruppen mit 1 bis 3 Kohlenstoffatomen, 1 bis 3 Alkoxygruppen mit 1 bis 3 Kohlenstoffatomen und 1 bis 3 Halogenatomen; und unsubstituiertem und substituiertem Phenylalkyl, wobei der Phenylrest, falls er substituiert ist, wie oben im Falle eines substituierten Phenyls substituiert ist und der Alkylrest eine Polyalkylengruppe mit 1 bis 3 Kohlenstoffatomen bedeutet;


m eine ganze Zahl bedeutet, die ausgewählt ist von 1 bis 10; und

Ab einen monoklonalen Antikörper mit einer daran hängenden Aminogruppe bedeutet; und wobei die Orientierung der Gruppe




am Phenylring der Benzylcarbamateinheit ausgewählt ist unter der ortho- und para-Position.


2. Verbindung nach Anspruch 1, wobei der Arzneistoffrest D ausgewählt ist unter Arzneistoffen mit einer primären Aminogruppe und einer sekundären Aminogruppe.
3. Verbindungen nach Anspruch 2, wobei der Arzneistoffrest D ausgewählt ist unter Mitomycin-C, Mitomycin-A, Daunomycin, Adriamycin, Aminopterin, Actinomycin, Bleomycin und Derivaten davon.
4. Verbindung nach Anspruch 1, wobei der Arzneistoffrest D ein Arzneistoff mit einer Alkoholgruppe ist.
5. Verbindung nach Anspruch 4, wobei der Arzneistoffrest D Etoposid ist.
6. Verfahren zur Herstellung der Konjugate der Ansprüche 1 bis 5, wobei man para- oder ortho-Mercaptobenzylalkohol mit PySCl, worin Py für Pyridyl, vorzugsweise 2-Pyridyl, oder 3-Nitrophenyl steht, zur Reaktion bringt, die so erhaltene Verbindung mit Trichlormethylchlorformiat in einem inerten organischen Lösungsmittel in Gegenwart einer Base, vorzugsweise Pyridin, umsetzt, die so erhaltene Verbindung mit einem Antitumorarzneistoff D, worin D die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten organischen Lösungsmittel und vorzugsweise in Gegenwart einer Base zu einer Verbindung der allgemeinen Formel



umsetzt,
die so erhaltene Verbindung mit einer Mercaptocarbonsäure der allgemeinen Formel:



worin R^3 , R^4 und m die in Anspruch 1 angegebenen Bedeutungen besitzen in einem inerten organischen Lösungsmittel zu einer Verbindung der allgemeinen Formel:



worin R ein Wasserstoffatom bedeutet, umsetzt,
die so erhaltene Carbonsäure mit N-Hydroxysuccinimid und einem Kondensationsmittel, vorzugsweise Dicyclohexylcarbodiimid, in einem inerten organischen Lösungsmittel zum Hydroxysuccinimidester der oben angegebenen allgemeinen Formel, worin R für




steht, umsetzt und
die so erhaltene Verbindung mit einem Antikörper Ab-NH_2 , worin Ab die in Anspruch 1 angegebenen Bedeutungen besitzt, in einem inerten Reaktionsmedium zur Reaktion bringt.

7. Verfahren zur Herstellung eines Arzneimittels, welches wenigstens ein Antikörperkonjugat nach einem der Ansprüche 1 bis 5 und einen pharmazeutisch verträglichen Träger und gegebenenfalls übliche pharmazeutisch verträgliche Exzipienten und Adjuvantien enthält, wobei man wenigstens eine Verbindung der Ansprüche 1 bis 5 einem pharmazeutisch verträglichen Träger und gegebenenfalls üblichen pharmazeutisch verträglichen Exzipienten und Adjuvantien einverleibt.
8. Verwendung wenigstens eines Antikörperkonjugates nach einem der Ansprüche 1 bis 5 zur Herstellung eines pharmazeutischen Mittels zur Tumorbehandlung.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Conjugué médicament antitumeur-anticorps monoclonal ayant la formule de structure générale :



dans laquelle :

D est un fragment d'un médicament antitumeur ayant, pendant à son arête, un groupe fonctionnel chimiquement réactif au moyen duquel l'arête du médicament se trouve liée au groupe disulfure de

benzyloxycarbonyle, choisi parmi un groupe amino primaire représenté par la formule R^1NH- , un groupe amino secondaire représenté par la formule R^1R^2N- et un groupe alcool représenté par la formule R^1O- ;

5 R^1 est l'arête dudit fragment de médicament quand D est dérivé d'un groupe amino primaire, d'un groupe amino secondaire et d'un groupe alcool où, dans le cas d'un groupe amino secondaire, R^1 et R^2 sont indépendants ;

R^2 , quand R^1 et R^2 sont indépendants, est choisi parmi des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1-10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué, est substitué comme décrit ci-dessus dans le cas du phényle substitué et le fragment alkyle est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;


15 R^1 et R^2 , quand ils sont pris ensemble dans un groupe fonctionnel dérivé d'une amine secondaire, représentent l'arête du fragment du médicament, D, ayant un groupe divalent chimiquement lié à l'atome d'azote constituant ledit groupe amino secondaire ; et

R^3 et R^4 , indépendamment, sont choisis parmi H et des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1 à 10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué, est substitué comme défini ci-dessus dans le cas du phényle substitué et le fragment alkyle est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;

m est un nombre entier choisi par 1 à 10 ; et

Ab représente un anticorps monoclonal ayant un groupe amino pendant ; et l'orientation du groupe,

30



35 sur le noyau phényle du fragment benzylcarbamate, est choisie parmi les positions ortho et para.


2. Composé selon la revendication 1, où le fragment de médicament, D, est un élément choisi par des médicaments contenant une amine primaire et contenant une amine secondaire.
- 40 3. Composé selon la revendication 2, où le fragment de médicament, D, est un élément choisi parmi mitomycine-C, mitomycine-A, daunomycine, adriamycine, aminoptérine, actinomycine, bléomycine et leurs dérivés.
4. Composé selon la revendication 1, où le fragment de médicament, D, est un médicament contenant un groupe alcool.
- 45 5. Composé selon la revendication 4, où le fragment du médicament, D, est l'étoposide.
6. Procédé de préparation des conjugués des revendications 1 à 5, qui comprend la réaction de l'alcool para- ou ortho- mercaptobenzylque avec $PySCl$, où Py est pyridyle, de préférence 2-pyridyle, ou 3-nitrophenyle, la réaction du composé ainsi obtenu avec du trichlorométhylchloroformiate dans un solvant organique inerte en présence d'une base, de préférence la pyridine, la réaction du composé ainsi obtenu avec un médicament D antitumoral, où D est tel que défini à la revendication 1, dans un solvant organique inerte et, de préférence, en présence d'une base, pour obtenir un composé de la formule générale
- 55



la réaction du composé ainsi obtenu avec un acide mercapto-carboxylique de la formule générale



où R^3 , R^4 et m sont tels que définis à la revendication 1, dans un solvant organique inerte, pour obtenir un composé de la formule générale :



où R est hydrogène,

la réaction de l'acide carboxylique ainsi obtenu avec du N-hydroxysuccinimide et un agent de condensation, de préférence le dicyclohexyl carbodiimide, dans un solvant organique inerte, pour obtenir l'ester d'hydroxysuccinimide de la formule générale ci-dessus, où R est



et la réaction du composé ainsi obtenu avec un anticorps Ab-NH_2 , où Ab est tel que défini à la revendication 1, dans un milieu réactionnel inerte.


7. Composition pharmaceutique comprenant au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 et son support acceptable en pharmacie et, facultativement, des excipients ou adjuvants conventionnels acceptables en pharmacie.

8. Procédé de préparation de la composition de la revendication 7, qui comprend l'incorporation d'au moins un composé des revendications 1 à 5 dans un support acceptable en pharmacie et, facultativement, les excipients et adjuvants conventionnels acceptables en pharmacie.

9. Utilisation d'au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 pour la préparation d'une composition pharmaceutique pour le traitement des tumeurs.

Revendications pour l'Etat contactant suivant : ES

1. Procédé de préparation d'un conjugué médicament antitumeur-anticorps monoclonal ayant la formule de structure générale :



dans laquelle :

D est un fragment d'un médicament antitumeur ayant, pendant à son arête, un groupe fonctionnel chimiquement réactif, au moyen duquel l'arête du médicament est liée au groupe disulfure de dibenzoyloxycarbonyle, choisi parmi un groupe amino primaire représenté par la formule R^1NH- , un groupe amino secondaire représenté par la formule R^1R^2N- et un groupe alcool représenté par la formule R^1O- ;

R^1 est l'arête dudit fragment du médicament quand D est dérivé d'un groupe amino primaire, d'un groupe amino secondaire et d'un groupe alcool où, dans le cas d'un groupe amino secondaire, R^1 et R^2 sont indépendants,


R^2 , quand R^1 et R^2 sont indépendants, est choisi parmi des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1-10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué comme défini ci-dessus dans le cas du phényle substitué et du fragment alkyle, est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;

R^1 et R^2 , quand ils sont pris ensemble dans un groupe fonctionnel dérivé d'une amine secondaire, représentent l'arête du fragment du médicament, D, ayant un groupe divalent qui est chimiquement lié à l'atome d'azote constituant ledit groupe amino secondaire ; et

R^3 et R^4 , indépendamment, sont choisis parmi H et des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1-10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué, est substitué comme défini ci-dessus dans le cas du phényle substitué et le fragment alkyle est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;

m est un nombre entier choisi par 1 à 10 ; et


Ab représente un anticorps monoclonal ayant un groupe amino pendant ; et l'orientation du groupe




sur le noyau phényle du fragment benzylcarbamate, est choisie parmi les positions ortho et para, qui comprend la réaction de l'alcool para- ou orthomercaptobenzyle avec $PsSCl$, où Py est pyridyle, de préférence 2-pyridyle ou 3-nitrophényle,

la réaction du composé ainsi obtenu avec du trichlorométhylchloroformiate dans un solvant organique inerte en présence d'une base, de préférence la pyridine,


la réaction du composé ainsi obtenu avec un médicament, D, antitumeur où D est tel que défini ci-dessus, dans un solvant organique inerte et, de préférence, en présence d'une base, pour obtenir un composé de la formule générale



la réaction du composé ainsi obtenu avec un acide mercapto-carboxylique de la formule générale ;



où R^3 , R^4 et m sont tels que définis ci-dessus, dans un solvant organique inerte, pour obtenir un composé de la formule générale ;



où R est hydrogène,

la réaction de l'acide carboxylique ainsi obtenu avec du N-hydroxysuccinimide et un agent de condensation, de préférence le dicyclohexyl carbodiimide, dans un solvant organique inerte, pour obtenir l'ester d'hydroxysuccinimide de la formule générale ci-dessus, où R est



et la réaction du composé ainsi obtenu avec un anticorps Ab-NH_2 , où Ab est tel que défini ci-dessus, dans un milieu réactionnel inerte.

2. Procédé selon la revendication 1, où le fragment du médicament, D , est un élément choisi parmi des médicaments contenant une amine primaire et contenant une amine secondaire.
3. Procédé selon la revendication 2, où le fragment du médicament, D , est un élément choisi parmi mitomycine-C, mitomycine-A, daunomycine, adriamycine, aminoptérine, actinomycine, bléomycine et leurs dérivés.
4. Procédé selon la revendication 1, où le fragment du médicament, D , est un médicament contenant un groupe alcool.
5. Procédé selon la revendication 4, où le fragment du médicament, D , est l'étoposide.
6. Procédé de préparation d'une composition pharmaceutique comprenant au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 et un support acceptable en pharmacie et facultativement, des excipients et adjuvants traditionnels acceptables en pharmacie, qui comprend l'incorporation d'au moins un composé des revendications 1 à 5, dans un support acceptable en pharmacie et facultativement, des excipients et adjuvants traditionnels acceptables en pharmacie.
7. Utilisation d'au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 pour la

préparation d'une composition pharmaceutique pour le traitement des tumeurs.

Revendications pour l'Etat contractant suivant : GR

1. Conjugué médicament antitumeur-anticorps monoclonal ayant la formule de structure générale :



dans laquelle :

D est un fragment d'un médicament antitumeur ayant, pendant à son arête, un groupe fonctionnel chimiquement réactif, au moyen duquel l'arête du médicament est liée au groupe disulfure de benzyloxycarbonyl, choisi parmi un groupe amino primaire représenté par la formule R^1NH- , un groupe amino secondaire représenté par la formule R^1R^2N- et un groupe alcool représenté par la formule R^1O- ;

R^1 est l'arête dudit fragment du médicament quand D est dérivé d'un groupe amino primaire, d'un groupe amino secondaire et d'un groupe alcool où dans le cas du groupe amino secondaire, R^1 et R^2 sont indépendants ;

R^2 , quand R^1 et R^2 sont indépendants, est choisi parmi des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1-10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupe, alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué, est substitué comme défini ci-dessus dans le cas du phényle substitué et le fragment alkyle est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;

R^1 et R^2 , lorsqu'ils sont pris ensemble dans un groupe fonctionnel dérivé d'une amine secondaire, représentent l'arête du fragment du médicament, D, ayant un groupe divalent qui est chimiquement lié à l'atome d'azote constituant ledit groupe amino secondaire ; et

R^3 et R^4 , indépendamment, sont choisis parmi H et des groupes alkyles non substitués et substitués et ramifiés et à chaîne droite ayant 1-10 atomes de carbone où le substituant est choisi parmi 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; phényle non substitué et substitué où le substituant est choisi parmi 1 à 3 groupes alkyles ayant 1 à 3 atomes de carbone, 1 à 3 groupes alcoxy ayant 1 à 3 atomes de carbone et 1 à 3 groupes halo ; et phénylalkyle non substitué et substitué où le fragment phényle, quand il est substitué, est substitué comme on l'a défini ci-dessus dans le cas du phényle substitué et le fragment alkyle est un groupe polyalkylène ayant 1 à 3 atomes de carbone ;

m est un nombre entier choisi parmi 1 à 10 ; et

Ab représente un anticorps monoclonal ayant un groupe amino pendant ; et l'orientation du groupe,




sur le noyau phényle du fragment benzyloxycarbonyl, est choisie parmi les positions ortho et para.

2. Composé selon la revendication 1, où le fragment du médicament, D, est un élément choisi parmi des médicaments contenant une amine primaire et contenant une amine secondaire.


3. Composé selon la revendication 2, où le fragment du médicament, D, est un élément choisi parmi mitomycine-C, mitomycine-A, daunomycine, adriamycine, aminoptérine, actinomycine, bléomycine et leurs dérivés.
- 5 4. Composé selon la revendication 1, où le fragment du médicament, D, est un médicament contenant un groupe alcool.
5. Composé selon la revendication 4, où le fragment du médicament D, est l'étoposide.
- 10 6. Procédé de préparation des conjugués des revendications 1 à 5, qui comprend la réaction de l'alcool para ou ortho-mercaptobenzyle avec PySCl, où Py est pyridyle, de préférence 2-pyridyle ou 3-nitrophényle,
- la réaction du composé ainsi obtenu avec du trichlorométhylchloroformate dans un solvant organique inerte en présence d'une base, de préférence la pyridine,
- 15 la réaction du composé ainsi obtenu avec un médicament antitumeur D, où D est tel que défini à la revendication 1 dans un solvant organique inerte et, de préférence, en présence d'une base, pour obtenir un composé de la formule générale




25 la réaction du composé ainsi obtenu avec un acide mercapto-carboxylique de la formule générale



30 où R³, R⁴ et m sont tels que définis à la revendication 1, dans un solvant organique inerte, pour obtenir un composé de la formule générale :



40 où R est hydrogène, la réaction de l'acide carboxylique ainsi obtenu avec du N-hydroxysuccinimide et un agent de condensation, de préférence le dicyclohexyl carbodiimide, dans un solvant organique inerte, pour obtenir l'ester d'hydroxysuccinimide de la formule générale ci-dessus où R est



55 et la réaction du composé ainsi obtenu avec un anticorps Ab-NH₂, où Ab est tel que défini à la revendication 1, dans un milieu réactionnel inerte.

7. Procédé de préparation d'une composition pharmaceutique comprenant au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 et un support acceptable en pharmacie et,

facultativement, des excipients et adjuvants traditionnels acceptables en pharmacie, qui comprend l'incorporation d'au moins un composé des revendications 1 à 5 dans un support acceptable en pharmacie et, facultativement des excipients et adjuvants traditionnels acceptables en pharmacie.

5

8. Utilisation d'au moins un conjugué d'anticorps selon l'une quelconque des revendications 1 à 5 pour la préparation d'une composition pharmaceutique pour le traitement des tumeurs.

10

15

20

25

30

35

40

45

50

55

FIGURE 1




FIGURE 2









FIGURE 3

